Aarhus University Seal / Aarhus Universitets segl

Asbjørn Mohr Drewes

Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. / Andresen, Trine; Staahl, C; Oksche, A; Mansikka, H; Arendt-Nielsen, Lars; Drewes, Am.

I: British Journal of Pharmacology, Bind 164, Nr. 3, 23.12.2011, s. 934-45.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Andresen, T, Staahl, C, Oksche, A, Mansikka, H, Arendt-Nielsen, L & Drewes, A 2011, 'Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain', British Journal of Pharmacology, bind 164, nr. 3, s. 934-45. https://doi.org/10.1111/j.1476-5381.2010.01180.x

APA

Andresen, T., Staahl, C., Oksche, A., Mansikka, H., Arendt-Nielsen, L., & Drewes, A. (2011). Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. British Journal of Pharmacology, 164(3), 934-45. https://doi.org/10.1111/j.1476-5381.2010.01180.x

CBE

Andresen T, Staahl C, Oksche A, Mansikka H, Arendt-Nielsen L, Drewes A. 2011. Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. British Journal of Pharmacology. 164(3):934-45. https://doi.org/10.1111/j.1476-5381.2010.01180.x

MLA

Vancouver

Andresen T, Staahl C, Oksche A, Mansikka H, Arendt-Nielsen L, Drewes A. Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. British Journal of Pharmacology. 2011 dec 23;164(3):934-45. https://doi.org/10.1111/j.1476-5381.2010.01180.x

Author

Andresen, Trine ; Staahl, C ; Oksche, A ; Mansikka, H ; Arendt-Nielsen, Lars ; Drewes, Am. / Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. I: British Journal of Pharmacology. 2011 ; Bind 164, Nr. 3. s. 934-45.

Bibtex

@article{f56f4daeddda4b619545d6bc1d4f9ecb,
title = "Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain",
abstract = "Background and purpose: Chronic pain and hyperalgesia can be difficult to treat with classical opioids acting predominately at the µ-opioid receptor. Buprenorphine and its active metabolite are believed to act through µ-, κ- and δ-receptors and may therefore possess different analgesic and anti-hyperalgesic effects compared to pure µ-receptor agonists e.g. fentanyl. Here, we have compared the analgesic and anti-hyperalgesic effects of buprenorphine and fentanyl. Experimental approach: 22 healthy volunteers were randomized to treatment with transdermal buprenorphine (20µg/h, 144h), fentanyl (25µg/h, 72h) or placebo patches in a double-blind, cross-over experimental pain study. The experimental pain tests (phasic pain, sensitization) involved pressure at the tibial bone, cutaneous electrical and thermal stimulation, intramuscular nerve growth factor, UV-B light burn injury model and intradermal capsaicin-induced hyperalgesia. Pain testing was carried out at baseline, 24, 48, 72 and 144 hours after application of the drugs. Key Results: Compared to placebo, buprenorphine, but not fentanyl, significantly attenuated pressure at the tibial bone as well as pressure pain in the primary hyperalgesic area induced by UV-B light The two drugs were equipotent and better than placebo against cutaneous thermal pain stimulation), but failed to show significant analgesic effect to cutaneous electrical stimulation, nerve growth factor-induced muscle soreness and to capsaicin-induced hyperalgesia. Conclusions and implications: Buprenorphine, but not fentanyl, showed analgesic effects against experimentally induced, bone-associated pain and primary hyperalgesia compared to placebo. These tissue- and modality-differentiated properties may reflect the variable effects of opioid drugs observed in individual patients.",
author = "Trine Andresen and C Staahl and A Oksche and H Mansikka and Lars Arendt-Nielsen and Am Drewes",
note = "{\textcopyright} 2010 The Authors. British Journal of Pharmacology {\textcopyright} 2010 The British Pharmacological Society.",
year = "2011",
month = dec,
day = "23",
doi = "10.1111/j.1476-5381.2010.01180.x",
language = "English",
volume = "164",
pages = "934--45",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John/Wiley & Sons Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain

AU - Andresen, Trine

AU - Staahl, C

AU - Oksche, A

AU - Mansikka, H

AU - Arendt-Nielsen, Lars

AU - Drewes, Am

N1 - © 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

PY - 2011/12/23

Y1 - 2011/12/23

N2 - Background and purpose: Chronic pain and hyperalgesia can be difficult to treat with classical opioids acting predominately at the µ-opioid receptor. Buprenorphine and its active metabolite are believed to act through µ-, κ- and δ-receptors and may therefore possess different analgesic and anti-hyperalgesic effects compared to pure µ-receptor agonists e.g. fentanyl. Here, we have compared the analgesic and anti-hyperalgesic effects of buprenorphine and fentanyl. Experimental approach: 22 healthy volunteers were randomized to treatment with transdermal buprenorphine (20µg/h, 144h), fentanyl (25µg/h, 72h) or placebo patches in a double-blind, cross-over experimental pain study. The experimental pain tests (phasic pain, sensitization) involved pressure at the tibial bone, cutaneous electrical and thermal stimulation, intramuscular nerve growth factor, UV-B light burn injury model and intradermal capsaicin-induced hyperalgesia. Pain testing was carried out at baseline, 24, 48, 72 and 144 hours after application of the drugs. Key Results: Compared to placebo, buprenorphine, but not fentanyl, significantly attenuated pressure at the tibial bone as well as pressure pain in the primary hyperalgesic area induced by UV-B light The two drugs were equipotent and better than placebo against cutaneous thermal pain stimulation), but failed to show significant analgesic effect to cutaneous electrical stimulation, nerve growth factor-induced muscle soreness and to capsaicin-induced hyperalgesia. Conclusions and implications: Buprenorphine, but not fentanyl, showed analgesic effects against experimentally induced, bone-associated pain and primary hyperalgesia compared to placebo. These tissue- and modality-differentiated properties may reflect the variable effects of opioid drugs observed in individual patients.

AB - Background and purpose: Chronic pain and hyperalgesia can be difficult to treat with classical opioids acting predominately at the µ-opioid receptor. Buprenorphine and its active metabolite are believed to act through µ-, κ- and δ-receptors and may therefore possess different analgesic and anti-hyperalgesic effects compared to pure µ-receptor agonists e.g. fentanyl. Here, we have compared the analgesic and anti-hyperalgesic effects of buprenorphine and fentanyl. Experimental approach: 22 healthy volunteers were randomized to treatment with transdermal buprenorphine (20µg/h, 144h), fentanyl (25µg/h, 72h) or placebo patches in a double-blind, cross-over experimental pain study. The experimental pain tests (phasic pain, sensitization) involved pressure at the tibial bone, cutaneous electrical and thermal stimulation, intramuscular nerve growth factor, UV-B light burn injury model and intradermal capsaicin-induced hyperalgesia. Pain testing was carried out at baseline, 24, 48, 72 and 144 hours after application of the drugs. Key Results: Compared to placebo, buprenorphine, but not fentanyl, significantly attenuated pressure at the tibial bone as well as pressure pain in the primary hyperalgesic area induced by UV-B light The two drugs were equipotent and better than placebo against cutaneous thermal pain stimulation), but failed to show significant analgesic effect to cutaneous electrical stimulation, nerve growth factor-induced muscle soreness and to capsaicin-induced hyperalgesia. Conclusions and implications: Buprenorphine, but not fentanyl, showed analgesic effects against experimentally induced, bone-associated pain and primary hyperalgesia compared to placebo. These tissue- and modality-differentiated properties may reflect the variable effects of opioid drugs observed in individual patients.

U2 - 10.1111/j.1476-5381.2010.01180.x

DO - 10.1111/j.1476-5381.2010.01180.x

M3 - Journal article

C2 - 21182491

VL - 164

SP - 934

EP - 945

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -